{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:16:46Z","timestamp":1794082606851,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007344","name":"Achmea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007344","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ajog.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T16:44:56Z","timestamp":1744303496000},"page":"250-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7023-0274","authenticated-orcid":false,"given":"Rosalie J.","family":"Hup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna A.A.","family":"Damen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonne","family":"Terstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirthe J.","family":"Klein Haneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fieke","family":"Terstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Titia","family":"Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Depmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2025.04.011_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.preghy.2018.05.004","article-title":"The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice","volume":"13","author":"Brown","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2025.04.011_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/2050312119843700","article-title":"Hypertension in pregnancy: pathophysiology and treatment","volume":"7","author":"Braunthal","year":"2019","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.ajog.2025.04.011_bib3","first-page":"1122","article-title":"Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on hypertension in pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/1471-0528.12737","article-title":"Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review","volume":"121","author":"Firoz","year":"2014","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2025.04.011_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.ackd.2019.03.017","article-title":"Hypertension and pregnancy: management and future risks","volume":"26","author":"Reddy","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ajog.2025.04.011_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ajog.2020.03.016","article-title":"Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis","volume":"223","author":"Bellos","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib7","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"10","author":"Abalos","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2025.04.011_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1089\/jwh.2018.7145","article-title":"Review of cardiovascular drugs in pregnancy","volume":"28","author":"Kaye","year":"2019","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.ajog.2025.04.011_bib9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.semperi.2015.08.011","article-title":"A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy","volume":"39","author":"Clark","year":"2015","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2025.04.011_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/HJH.0000000000000069","article-title":"Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations","volume":"32","author":"Al Khaja","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.ajog.2025.04.011_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","article-title":"The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice","volume":"27","author":"Magee","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2025.04.011_bib12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/HYPERTENSIONAHA.121.18415","article-title":"Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses","volume":"79","author":"Bone","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2025.04.011_bib13","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMc1503870","article-title":"Less-tight versus tight control of hypertension in pregnancy","volume":"372","author":"Tita","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2025.04.011_bib14","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.116.07862","article-title":"The CHIPS randomized controlled trial (control of hypertension in pregnancy study): is severe hypertension just an elevated blood pressure?","volume":"68","author":"Magee","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2025.04.011_bib15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.medcli.2016.02.025","volume":"147","author":"Hutton","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.ajog.2025.04.011_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ajog.2025.04.011_bib17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/1471-0528.16319","article-title":"A core outcome set for pre-eclampsia research: an international consensus development study","volume":"127","author":"Duffy","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2025.04.011_bib18","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2025.04.011_bib19","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020. Available at: https:\/\/test-training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/review-manager-revman\/download-revman-5. Accessed February 2, 2024."},{"key":"10.1016\/j.ajog.2025.04.011_bib20","series-title":"Meta-analysis with R","author":"Schwarzer","year":"2015"},{"key":"10.1016\/j.ajog.2025.04.011_bib21","first-page":"40","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"1","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ajog.2025.04.011_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41073-023-00130-8","article-title":"Checklist to assess Trustworthiness in RAndomised Controlled Trials (TRACT checklist): concept proposal and pilot","volume":"8","author":"Mol","year":"2023","journal-title":"Res Integr Peer Rev"},{"key":"10.1016\/j.ajog.2025.04.011_bib23","article-title":"Comparative study of efficacy of methyldopa vs labetalol in the management of pregnancy induced hypertension in respect to maternal and perinatal outcomes","volume":"4","author":"Roychoudhury","year":"2015","journal-title":"Glob J Med Public Heal"},{"key":"10.1016\/j.ajog.2025.04.011_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.33545\/gynae.2020.v4.i1d.473","article-title":"Comparision of efficacy of labetalol vs nifedipine in pregnancy induced hypertension","volume":"4","author":"Prasanthi","year":"2020","journal-title":"Int J Clin Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib25","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1016\/S0020-7292(09)61629-5","article-title":"Role of labetolol and nifedipine in management of pregnancy-induced hypertension in third trimester of pregnancy - a comparative clinical study","volume":"107","author":"Phukan","year":"2009","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ajog.2025.04.011_bib26","series-title":"The use of nifedipine vs methyldopa in mild to moderate pregnancy associated hypertension","first-page":"130","author":"Eloff","year":"1993"},{"key":"10.1016\/j.ajog.2025.04.011_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.53350\/pjmhs211571703","article-title":"Comparison between methyldopa and combination of methyldopa and nifedipine in terms of mean change in blood pressure in pregnancy induced hypertension","volume":"15","author":"Akhtar Malik","year":"2021","journal-title":"Pak J Med Health Sci"},{"key":"10.1016\/j.ajog.2025.04.011_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.53350\/pjmhs2023172256","article-title":"Oral labetalol in comparison with methyldopa in treatment of gestational hypertension as a first line drug","volume":"17","author":"Akhter","year":"2023","journal-title":"Pak J Med Health Sci"},{"key":"10.1016\/j.ajog.2025.04.011_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/01443619209004032","article-title":"Intra-uterine growth retardation and maternal labetatol treatment in a random allocation controlled study","volume":"12","author":"Cruickshank","year":"1992","journal-title":"Obstet Gynaecol (Lahore)"},{"key":"10.1016\/j.ajog.2025.04.011_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0028-2243(92)90192-2","article-title":"Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study","volume":"45","author":"Cruickshank","year":"1992","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2025.04.011_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/10641959109012919","article-title":"Maternal obstetric outcome measures in A randomised controlled study of labetalol in the treatment of hypertension in pregnancy","volume":"10","author":"Cruickshank","year":"1991","journal-title":"Clin Exp Hypertens Part B Hypertens Pregnancy"},{"key":"10.1016\/j.ajog.2025.04.011_bib32","first-page":"3271","article-title":"Management of pregnancy induced hypertension (PIH) by Methyldopa versus labetalol - a randomized controlled trial","volume":"10","author":"Digra","year":"2023","journal-title":"Eur J Mol Clin Med"},{"key":"10.1016\/j.ajog.2025.04.011_bib33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(19)31282-6","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial","volume":"394","author":"Easterling","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2025.04.011_bib34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4314\/eamj.v79i4.8872","article-title":"Methyldopa versus no drug treatment in the management of mild pre-eclampsia","volume":"79","author":"Elhassan","year":"2002","journal-title":"East Afr Med J"},{"key":"10.1016\/j.ajog.2025.04.011_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0020-7292(95)02351-C","article-title":"Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension","volume":"49","author":"el-Qarmalawi","year":"1995","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2025.04.011_bib36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3109\/10641968009037147","article-title":"Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension","volume":"2","author":"Lamming","year":"1978","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.ajog.2025.04.011_bib37","first-page":"226","article-title":"Role of labetalol and methyldopa in newly diagnosed mild hypertension in pregnancy: a prospective drug comparative study in a rural tertiary care hospital in India","volume":"8","author":"Maheshwari","year":"2017","journal-title":"Int J Pharm Sci Res"},{"key":"10.1016\/j.ajog.2025.04.011_bib38","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00404-011-2205-2","article-title":"Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa","volume":"285","author":"Molvi","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2025.04.011_bib39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1471-0528.1998.tb10201.x","article-title":"Nifedipine versus expectant management in mild to moderate hypertension in pregnancy","volume":"105","year":"1998","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1185\/03007998209110129","article-title":"The treatment of hypertension in pregnancy","volume":"8","author":"Moore","year":"1982","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.ajog.2025.04.011_bib41","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1471-0528.1992.tb13698.x","article-title":"A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension","volume":"99","author":"Pickles","year":"1992","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1471-0528.1989.tb01574.x","article-title":"The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension","volume":"96","author":"Pickles","year":"1989","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib43","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1471-0528.1988.tb06571.x","article-title":"Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial","volume":"95","author":"Plouin","year":"1988","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib44","first-page":"793","article-title":"Oral labetalol versus oral methyldopa for the management pregnancy induced hypertension","volume":"15","author":"Rauf","year":"2021","journal-title":"Pak J Med Health Sci"},{"key":"10.1016\/j.ajog.2025.04.011_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(76)90597-3","article-title":"Fetal outcome in trial of antihypertensive treatment in pregnancy","volume":"2","author":"Redman","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2025.04.011_bib46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0002-9378(12)80005-6","article-title":"A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term","volume":"167","author":"Sibai","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib47","first-page":"323","article-title":"A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term","volume":"70","author":"Sibai","year":"1987","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib48","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0002-9378(90)91297-P","article-title":"A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy","volume":"162","author":"Sibai","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib49","first-page":"148","article-title":"Labetalol in pregnancy-induced hypertension: fetal and maternal effects","volume":"159","author":"Walker","year":"1982","journal-title":"Int Congr Ser"},{"key":"10.1016\/j.ajog.2025.04.011_bib50","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/HYPERTENSIONAHA.117.09972","article-title":"Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial","volume":"70","author":"Webster","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2025.04.011_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0020-7292(87)90181-0","article-title":"Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study","volume":"25","author":"Weitz","year":"1987","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 1","key":"10.1016\/j.ajog.2025.04.011_bib52","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/BF01428396","article-title":"Effect of antihypertensive drugs on glomerular hyperfiltration and renal haemodynamics. Comparison of captopril with nifedipine, metoprolol and celiprolol","volume":"44","author":"Bohler","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2025.04.011_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/AOG.0000000000005613","article-title":"Pregnancy outcomes of nifedipine compared with labetalol for oral treatment of mild chronic hypertension","volume":"144","author":"Sanusi","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.04.011_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2023.101085","article-title":"Improving trustworthiness in research in Women's Health: a collective effort by OBGYN editors","volume":"5","author":"Berghella","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"10.1016\/j.ajog.2025.04.011_bib55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/jhh.2016.50","article-title":"A prediction model for the response to oral labetalol for the treatment of antenatal hypertension","volume":"31","author":"Stott","year":"2017","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ajog.2025.04.011_bib56","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/ajh.2010.105","article-title":"Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial","volume":"23","author":"Gupta","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ajog.2025.04.011_bib57","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s13063-023-07582-9","article-title":"A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA)","volume":"24","author":"Ashworth","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.ajog.2025.04.011_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020998","article-title":"Hypertensive pregnancy complications in women with epilepsy and antiepileptic drugs: a population-based cohort study of first pregnancies in Norway","volume":"8","author":"Danielsson","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajog.2025.04.011_bib59","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/HYPERTENSIONAHA.122.18920","article-title":"Role of antihypertensive treatment and blood pressure control in the occurrence of adverse pregnancy outcomes: a population-based study of linked electronic health records","volume":"79","author":"Al Khalaf","year":"2022","journal-title":"Hypertension"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825002182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825002182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:31:31Z","timestamp":1761431491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937825002182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0002937825002182"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2025.04.011","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}